Teva Pharmaceutical Industries (TEVA) stock plummeted over 11% in intraday trading on Wednesday, following the company's disappointing fourth-quarter earnings results and a gloomy outlook for 2025.
The Israeli pharmaceutical giant reported a significant decline in its Q4 non-GAAP earnings per share and revenue compared to the same period last year. TEVA's non-GAAP EPS for the quarter stood at $0.71, down from $1.00 a year earlier, while its revenue fell to $4.23 billion from $4.46 billion. Although the EPS met analysts' expectations, the revenue missed their forecast of $4.15 billion.
Moreover, TEVA's guidance for the full year 2025 fell short of analysts' projections. The company expects its 2025 non-GAAP diluted EPS to be in the range of $2.35 to $2.65 on revenue of $16.8 billion to $17.4 billion. Analysts had forecasted a non-GAAP EPS of $2.96 on revenue of $17.09 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.